Aardvark Therapeutics, Inc. (AARD)
| Market Cap | 119.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.59M |
| Shares Out | 21.82M |
| EPS (ttm) | -2.93 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,814 |
| Open | 5.48 |
| Previous Close | 5.52 |
| Day's Range | 5.41 - 5.70 |
| 52-Week Range | 3.35 - 17.94 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 15.29 (+180.04%) |
| Earnings Date | May 13, 2026 |
About AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AARD stock is "Buy." The 12-month stock price target is $15.29, which is an increase of 180.04% from the latest price.
News
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
SAN FRANCISCO, April 28, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that...
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman
SAN FRANCISCO, April 22, 2026 /PRNewswire/ - On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that it s...
Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman
SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- On March 2, 2026, investors in Aardvark Therapeutics (NASDAQ: AARD) saw the price of their shares crater $7.02 (-56%) after the company announced that...
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026
Aardvark Therapeutics, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, March 11, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Aardvark Therapeutics, Inc., ("Aardvark" or the "Company") (NASDAQ:AARD) investors that the firm has initiated an investiga...
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Aardvark Therape...
What's Going On With Aardvark Therapeutics Stock On Wednesday?
Aardvark Therapeutics Inc. (NASDAQ: AARD) on Monday announced to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.
Why Is Aardvark Therapeutics Stock Sinking Monday?
Aardvark Therapeutics Inc. (NASDAQ: AARD) shares are down during Monday's premarket session following the company's announcement to voluntarily pause its Phase 3 HERO trial for Prader-Willi Syndrome.
AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AARD--AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
SAN DIEGO, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark Therapeutics Announces Establishment of New U.S. Subsidiary to Support Development of Its Dermatology Pipeline; Bryan Jones Named Chief Executive Officer
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark Therapeutics Announces Leadership Appointments
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark Therapeutics Announces FDA Submission and IRB Approval of Amended Trial Protocol for Lead Candidate ARD-101, Expanding Eligibility in Phase 3 Study of Prader-Willi Syndrome
SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark's Hunger Suppressing Drug Candidate Could Potentially Address Massive $10 Billion Market: Analyst
Aardvark Therapeutics, Inc. (NASDAQ: AARD) is a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to suppress hunger for Prader-Willi Syndrome (PWS) and metaboli...
Aardvark Therapeutics Announces First Patient Dosed in Australia in HERO Phase 3 Trial for Prader-Willi Syndrome
Multiple active sites and strong US enrollment continue to support Q3 2026 timing for topline data readout Clinical trial sites in Canada and the United Kingdom have received regulatory clearance to e...
Aardvark Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
A novel oral small molecule targets gut-brain signaling to regulate hunger, with a single agent for rare disease and a combination for obesity. Early clinical and preclinical data show promising weight loss and body composition effects, with a phase III trial underway in Prader-Willi syndrome.
Aardvark Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Key programs target Prader-Willi syndrome and obesity, with ARD-101 in phase 3 and ARD-201 in phase 2. Phase 3 data for Prader-Willi is expected in Q3 2026, while preliminary obesity data is anticipated by end of next year.
Aardvark Therapeutics to Present at Upcoming Investor Conferences in December
SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark Therapeutics Transcript: TD Cowen Treatment Advancements in Obesity and Related Disorders Summit
The summit highlighted a novel gut-brain signaling approach for obesity and Prader-Willi syndrome, with ARD-101 and ARD-201 showing promising preclinical and early clinical results. Key phase II and III trials are underway, with initial data expected in 2026.
Aardvark Therapeutics Reports Third Quarter 2025 Financial Results and Provides Pipeline and Business Updates
Aardvark has aligned with the FDA to reduce the minimum age of eligibility from 13 to 10 years old for pediatric patients in HERO, the Phase 3 trial of ARD-101 for the treatment of hyperphagia associa...
Aardvark Therapeutics Transcript: Stifel 2025 Healthcare Conference
ARD-101, a gut-restricted oral drug, showed rapid and robust reduction in hyperphagia and metabolic improvements in Prader-Willi syndrome, with phase III results expected in Q3 2026. The combination ARD-201 demonstrated strong preclinical weight loss, and clinical obesity data are anticipated next year.
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
Aardvark Therapeutics Transcript: Study Update
ARD-101 is progressing into a global phase III HERO trial for Prader-Willi Syndrome, following phase II results showing significant hunger reduction and improved body composition. The trial is designed for broad accessibility and minimal disruption, with strong advocacy support and a focus on addressing major unmet needs in hyperphagia and related symptoms.
Aardvark Therapeutics Presents Data Supporting its Metabolic Obesity Pipeline Programs at ObesityWeek 2025
New preclinical results demonstrate the potential of ARD-201 in enhanced glucose control, along with preservation of lean mass, underscoring its opportunity in addressing key challenges in today's obe...